Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of KCI002 in pediatric patients with constipation
jRCT2031220631Phase 3Completed
- Sponsor
- Magmitt Pharmaceutical
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of magnesium oxide in constipation (4 arms), sponsored by Magmitt Pharmaceutical. Primary endpoint: Frequency of spontaneous bowel movement. Started Feb 2023; status: completed.
02
Drugs
magnesium oxide
03
Conditions
constipation
Beyond the preview
Go deeper on jRCT2031220631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220631.